BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)

Completed · Phase 4 · Has a placebo group

Conditions studied: Congestive Heart Failure Exacerbation, Renal Insufficiency

In brief

Many patients with exacerbations of heart failure have significant concomitant kidney dysfunction. The combination of these two conditions makes pharmacological management difficult. In this study, we plan to randomize patients with heart failure and kidney dysfunction to receive infusions of Natrecor (B-type Natriuretic Peptide)--which may be beneficial to the management of these two diseases--or placebo.

Key facts

Study ID

NCT00186329

Run by

Stanford University

People needed

100

Starts

2004-03-01

Expected to finish

2006-10-01

Last updated by the study team

2015-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• acute admission to hospital with CHF exacerbation
• calculated creatinine clearance between 15-60ml/min using the Cockroft Gault equation.

You may not qualify if…

• hypotension (SBP < 90mmHg)
• hypertension (SBP > 170 mmHg) necessitating vasodilator therapy
• known allergy to Natrecor
• history of heart transplantation
• contraindications to vasodilator therapy (i.e. severe aortic stenosis)
• up-front use of inotropes
• mental incompetence meaning inability to provide informed consent

Where it is running

• Stanford University Medical Center — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.